Angela A. Armstrong

Array ( [id] => 19658520 [patent_doc_number] => 20240425585 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-26 [patent_title] => ANTI-TMEFF1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES [patent_app_type] => utility [patent_app_number] => 18/632662 [patent_app_country] => US [patent_app_date] => 2024-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54691 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18632662 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19379375 [patent_doc_number] => 20240269245 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => NUCLEIC ACID MOLECULES ENCODING CLOSTRIDIUM HISTOLYTICUM COLLAGENASE I AND METHODS OF PRODUCING THE SAME [patent_app_type] => utility [patent_app_number] => 18/615520 [patent_app_country] => US [patent_app_date] => 2024-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16608 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18615520 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19642936 [patent_doc_number] => 20240417456 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-19 [patent_title] => BIOPHARMACEUTICAL COMPOSITIONS AND RELATED METHODS [patent_app_type] => utility [patent_app_number] => 18/613481 [patent_app_country] => US [patent_app_date] => 2024-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37362 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18613481 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19642936 [patent_doc_number] => 20240417456 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-19 [patent_title] => BIOPHARMACEUTICAL COMPOSITIONS AND RELATED METHODS [patent_app_type] => utility [patent_app_number] => 18/613481 [patent_app_country] => US [patent_app_date] => 2024-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37362 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18613481 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19642936 [patent_doc_number] => 20240417456 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-19 [patent_title] => BIOPHARMACEUTICAL COMPOSITIONS AND RELATED METHODS [patent_app_type] => utility [patent_app_number] => 18/613481 [patent_app_country] => US [patent_app_date] => 2024-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37362 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18613481 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19554928 [patent_doc_number] => 20240366720 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-07 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING PULMONARY HYPERTENSION [patent_app_type] => utility [patent_app_number] => 18/593002 [patent_app_country] => US [patent_app_date] => 2024-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13272 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18593002 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19691331 [patent_doc_number] => 20250009876 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-09 [patent_title] => HUMANIZED ANTI-PACAP ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/581446 [patent_app_country] => US [patent_app_date] => 2024-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 105327 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18581446 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19318366 [patent_doc_number] => 20240239909 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-18 [patent_title] => Antagonistic CD40 Monoclonal Antibodies and Uses Thereof [patent_app_type] => utility [patent_app_number] => 18/441998 [patent_app_country] => US [patent_app_date] => 2024-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15377 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18441998 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19380975 [patent_doc_number] => 20240270845 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => ANTI-CD2 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/439510 [patent_app_country] => US [patent_app_date] => 2024-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 61289 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18439510 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19380975 [patent_doc_number] => 20240270845 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => ANTI-CD2 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/439510 [patent_app_country] => US [patent_app_date] => 2024-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 61289 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18439510 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19387933 [patent_doc_number] => 20240277803 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-22 [patent_title] => NME INHIBITORS AND METHODS OF USING NME INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/439331 [patent_app_country] => US [patent_app_date] => 2024-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29928 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18439331 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19570426 [patent_doc_number] => 20240374718 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-14 [patent_title] => ANTI-PRO/LATENT-MYOSTATIN ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/431294 [patent_app_country] => US [patent_app_date] => 2024-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31924 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18431294 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19299996 [patent_doc_number] => 20240228565 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-11 [patent_title] => AMELIORATION AND TREATMENT OF INFARCTION DAMAGE [patent_app_type] => utility [patent_app_number] => 18/413753 [patent_app_country] => US [patent_app_date] => 2024-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30916 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18413753 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19142197 [patent_doc_number] => 20240141022 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-02 [patent_title] => ANTIBODY-CYTOKINS ENGRAFTED PROTEINS AND METHODS OF US IN THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 18/396301 [patent_app_country] => US [patent_app_date] => 2023-12-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24454 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -43 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18396301 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19379318 [patent_doc_number] => 20240269188 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => METHODS FOR INDUCING AN IMMUNE RESPONSE BY ADMINISTERING ACTIVATED MESENCHYMAL STEM CELLS [patent_app_type] => utility [patent_app_number] => 18/390569 [patent_app_country] => US [patent_app_date] => 2023-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20190 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18390569 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20254873 [patent_doc_number] => 12427206 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-30 [patent_title] => Method of assessing regulation of an immune response to an administered agent by measuring activation of nodose ganglion neurons [patent_app_type] => utility [patent_app_number] => 18/505590 [patent_app_country] => US [patent_app_date] => 2023-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 0 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18505590 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19096426 [patent_doc_number] => 20240115653 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-11 [patent_title] => METHODS OF INHIBITING INTEGRIN ALPHA9BETA1 ACTIVITY [patent_app_type] => utility [patent_app_number] => 18/379847 [patent_app_country] => US [patent_app_date] => 2023-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19368 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18379847 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19202840 [patent_doc_number] => 20240174739 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-30 [patent_title] => PROPERDIN BINDING PROTEIN AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/459465 [patent_app_country] => US [patent_app_date] => 2023-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32704 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18459465 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20212589 [patent_doc_number] => 12409223 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-09 [patent_title] => Antagonistic CD40 monoclonal antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 18/453691 [patent_app_country] => US [patent_app_date] => 2023-08-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 17 [patent_no_of_words] => 12157 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18453691 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19300093 [patent_doc_number] => 20240228662 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2024-07-11 [patent_title] => ANTIBODIES AGAINST CD38 FOR TREATMENT OF MULTIPLE MYELOMA [patent_app_type] => utility [patent_app_number] => 18/235550 [patent_app_country] => US [patent_app_date] => 2023-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 88305 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18235550 [rel_patent_id] =>[rel_patent_doc_number] =>)